Desoximetasone
drug drugOn this page
Also known as A-41304DesoximetasonaDesoxymethasoneHOE 304HOE-304J83.644CNSC-759189R 2113R-2113StiedexStiedex lpStiedex lpnTopicortTopicort lpSID29215017SID855924SID56423147SID144204440SID170464795
Summary
Desoximetasone (CHEMBL1766) is an approved small-molecule anti-inflammatory drug (ATC D07AC03) targeting NR3C1; indicated across 3 conditions including psoriasis and skin disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D07AC03 (+1 more)
- Targets: 1 (NR3C1)
- Indications: 3 conditions
- Clinical trials: 5
- Chemistry: 376.5 Da · C22H29FO4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1766 |
| Name | Desoximetasone |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5311067 |
| ChEBI | CHEBI:691037 |
| ATC | D07AC03, D07XC02 |
| Molecular formula | C22H29FO4 |
| Molecular weight | 376.5 |
| InChIKey | VWVSBHGCDBMOOT-IIEHVVJPSA-N |
SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C
IUPAC name: (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
ChEBI definition: Dexamethasone in which the hydroxy group at the 17α position is substituted by hydrogen. A synthetic corticosteroid with glucocorticoid activity, it is used as an anti-inflammatory and anti-pruritic in the treatment of various skin disorders, including skin allergies and psoriasis.
Pharmacological roles (ChEBI): anti-inflammatory drug, antipruritic drug.
Also known as: A-41304, Desoximetasona, Desoximetasone, Desoxymethasone, HOE 304, HOE-304, J83.644C, NSC-759189, R 2113, R-2113, Stiedex, Stiedex lp
Patent coverage: 5,516 distinct patent families (21,922 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | Agonist | 8.93 | 0.9% | P04150 |
Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C, Androgen receptor, Glucocorticoid receptor, Progesterone receptor, Nuclear receptor subfamily 1 group I member 2, Muscarinic acetylcholine receptor M1, Nuclear receptor subfamily 1 group I member 2, Hypoxia-inducible factor 1-alpha, Bile salt export pump.
Bioactivity
ChEMBL activities: 9 potent at pChembl ≥ 5 of 12 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NR3C1 | 8.93 | Ki | 1.17 | nM | CHEMBL_ACT_7704546 |
| LMNA | 8.6 | Potency | 2.5 | nM | CHEMBL_ACT_3658138 |
| NR3C1 | 8.59 | IC50 | 2.57 | nM | CHEMBL_ACT_7704545 |
| HIF1A | 8.3 | Potency | 5 | nM | CHEMBL_ACT_4131809 |
| HIF1A | 8.3 | Potency | 5 | nM | CHEMBL_ACT_4519332 |
| PGR | 7.48 | AC50 | 33.1 | nM | CHEMBL_ACT_25204797 |
| AR | 6.02 | AC50 | 952.2 | nM | CHEMBL_ACT_25203864 |
| SMN1 | 5.95 | Potency | 1122 | nM | CHEMBL_ACT_3868549 |
| Q9R1A7 | 5 | EC50 | 10000 | nM | CHEMBL_ACT_15463823 |
Target pathways
Aggregated over 1 target gene(s): NR3C1.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 1 | NR3C1 |
| Nuclear Receptor transcription pathway | 1 | NR3C1 |
| SUMOylation of intracellular receptors | 1 | NR3C1 |
| PTK6 Expression | 1 | NR3C1 |
| Regulation of RUNX2 expression and activity | 1 | NR3C1 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 1 | NR3C1 |
| Potential therapeutics for SARS | 1 | NR3C1 |
| Regulation of NPAS4 gene transcription | 1 | NR3C1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| negative regulation of transcription by RNA polymerase II | 1 |
| regulation of gluconeogenesis | 1 |
| chromatin organization | 1 |
| regulation of DNA-templated transcription | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| apoptotic process | 1 |
| chromosome segregation | 1 |
| signal transduction | 1 |
| glucocorticoid metabolic process | 1 |
| response to wounding | 1 |
| gene expression | 1 |
| microglia differentiation | 1 |
| adrenal gland development | 1 |
| nuclear receptor-mediated steroid hormone signaling pathway | 1 |
| regulation of glucocorticoid biosynthetic process | 1 |
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| psoriasis | 4 | MONDO:0005083 | EFO:0000676 |
| skin disorder | 4 | MONDO:0005093 | EFO:0000701 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 3 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02983981 | PHASE4 | COMPLETED | Topical Psoriasis Study for Patients Receiving Biologic Therapy |
| NCT02985736 | PHASE4 | COMPLETED | Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray |
| NCT03050294 | PHASE4 | COMPLETED | Evaluating Treatment Resistant Dermatitis TaroIIR |
| NCT01018134 | PHASE2 | COMPLETED | Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study |
| NCT01043393 | PHASE2 | COMPLETED | Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
173 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| FULVESTRANT | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| PODOFILOX | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| ACENOCOUMAROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ALCLOMETASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| APREPITANT | ChEMBL | Phase 4 (approved) | NR3C1 |
| AURANOFIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BECLOMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BENZBROMARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE PHOSPHORIC ACID | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE VALERATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUDESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUTOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CHLORMADINONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CICLESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOBETASOL PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOFAZIMINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DANAZOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEFLAZACORT | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOXYCORTICOSTERONE PIVALATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXTROTHYROXINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIENESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIFLORASONE DIACETATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DOXORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DROSPIRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EFAVIRENZ | ChEMBL | Phase 4 (approved) | NR3C1 |
| ENZALUTAMIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EPLERENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ETHINYL ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| EXEMESTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FELODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUNISOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOCINOLONE ACETONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOROMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOXYMESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLURANDRENOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| GLUCAGON | ChEMBL | Phase 4 (approved) | NR3C1 |
| HALCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE BUTYRATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXOCOBALAMIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXYPROGESTERONE CAPROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| IDARUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISRADIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| KETOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LASOFOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LOTEPREDNOL ETABONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MASOPROCOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDROXYPROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDRYSONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MESTRANOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE HEMISUCCINATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLTESTOSTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METOPROLOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MIFEPRISTONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MITOTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MOMETASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MONTELUKAST | ChEMBL | Phase 4 (approved) | NR3C1 |
| NAFTOPIDIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NIMODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NOMEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORETHINDRONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTIMATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| OXYMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PONATINIB | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNICARBATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| QUINESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RACECADOTRIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RIBOFLAVIN 5’-PHOSPHATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| RIMEXOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
Related Atlas pages
- Genes: NR3C1
- Indicated for: psoriasis, skin disorder
- Drugs: Fulvestrant, Podofilox, Regorafenib, Acenocoumarol, Alclometasone Dipropionate, Amcinonide, Amiodarone, Aprepitant, Auranofin, Bazedoxifene, Beclomethasone Dipropionate, Benzbromarone, Betamethasone, Betamethasone Dipropionate, Betamethasone Phosphoric Acid, Betamethasone Valerate, Budesonide, Butoconazole, Candesartan Cilexetil, Canrenone, Chlormadinone, Ciclesonide, Clobetasol Propionate, Clofazimine, Clotrimazole, Cortisone, Danazol, Daunorubicin, Deflazacort, Desogestrel, Desonide, Desoxycorticosterone Pivalate, Dexamethasone, Dextrothyroxine, Dienestrol, Diethylstilbestrol, Diflorasone Diacetate, Doxorubicin, Drospirenone, Econazole, Efavirenz, Enzalutamide, Eplerenone, Estradiol, Estriol, Ethinyl Estradiol, Exemestane, Felodipine, Fludrocortisone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Fluorometholone, Fluoxymesterone, Flurandrenolide, Fluticasone Furoate, Fluticasone Propionate, Glucagon, Halcinonide, Hydrocortisone, Hydrocortisone Butyrate, Hydroxocobalamin, Hydroxyprogesterone Caproate, Idarubicin, Isoconazole, Isradipine, Ketoconazole, Lasofoxifene, Loteprednol Etabonate, Masoprocol, Medroxyprogesterone, Medrysone, Megestrol, Mestranol, Methylprednisolone, Methylprednisolone Hemisuccinate, Methyltestosterone, Metoprolol, Mifepristone, Mitotane, Mometasone Furoate, Montelukast, Naftopidil, Nimodipine, Nisoldipine, Norethindrone, Norgestimate, Norgestrel, Oxymetholone, Ponatinib, Prednicarbate, Prednisolone, Prednisone, Progesterone, Quinestrol, Racecadotril, RIBOFLAVIN 5’-PHOSPHATE, Rimexolone